Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator

被引:9
|
作者
Francia, Pietro [1 ]
Ziacchi, Matteo [2 ]
Adduci, Carmen [1 ]
Ammendola, Ernesto [3 ]
Pieragnoli, Paolo [4 ]
De Filippo, Paolo [5 ]
Rapacciuolo, Antonio [6 ]
Rella, Valeria [7 ]
Migliore, Federico [8 ]
Viani, Stefano [9 ]
Musumeci, Maria Beatrice [1 ]
Biagini, Elena [2 ]
Lovecchio, Mariolina [10 ]
Baldini, Rossella [1 ]
Falasconi, Giulio [11 ,12 ]
Autore, Camillo [1 ]
Biffi, Mauro [2 ]
Cecchi, Franco [4 ,7 ]
机构
[1] Univ Sapienza, St Andrea Hosp, Dept Clin & Mol Med, Cardiol, Rome, Italy
[2] Univ Bologna, Inst Cardiol, Dept Expt Diagnost & Specialty Med, Policlin S Orsola Malpighi, Bologna, Italy
[3] Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Naples, Italy
[4] Univ Florence, Careggi Univ Hosp, Florence, Italy
[5] Papa Giovanni XXIII Hosp, Bergamo, Italy
[6] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy
[7] San Luca Hosp, Ist Auxol Italiano, Dept Cardiovasc Neural & Metab Sci, IRCCS, Milan, Italy
[8] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy
[9] Univ Hosp Pisa, Cardiothorac & Vasc Dept, Cardiol Div 2, Pisa, Italy
[10] Boston Sci, Milan, Italy
[11] Univ Barcelona, Campus Clin, Barcelona, Spain
[12] IRCCS Humanitas Res Hosp, Milan, Italy
来源
EUROPACE | 2023年 / 25卷 / 09期
关键词
Hypertrophic cardiomyopathy; Implantable cardioverter-defibrillator; Subcutaneous implantable cardioverter-defibrillator; Device-related complications; SUDDEN CARDIAC DEATH; CARDIOVERTER-DEFIBRILLATOR; TASK-FORCE; INAPPROPRIATE SHOCKS; EUROPEAN-SOCIETY; PREVENTION; OUTCOMES; THERAPY; ICD; ASSOCIATION;
D O I
10.1093/europace/euad270
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The implantable cardioverter-defibrillator (ICD) is a life-saving therapy in patients with hypertrophic cardiomyopathy (HCM) at risk of sudden cardiac death. Implantable cardioverter-defibrillator complications are of concern. The subcutaneous ICD (S-ICD) does not use transvenous leads and is expected to reduce complications. However, it does not provide bradycardia and anti-tachycardia pacing (ATP). The aim of this study was to compare appropriate and inappropriate ICD interventions, complications, disease-related adverse events and mortality between HCM patients implanted with a S- or transvenous (TV)-ICD.Methods and results Consecutive HCM patients implanted with a S- (n = 216) or TV-ICD (n = 211) were enrolled. Propensity-adjusted cumulative Kaplan-Meier curves and multivariate Cox proportional hazard ratios were used to compare 5-year event-free survival and the risk of events. The S-ICD patients had lower 5-year risk of appropriate (HR: 0.32; 95%CI: 0.15-0.65; P = 0.002) and inappropriate (HR: 0.44; 95%CI: 0.20-0.95; P = 0.038) ICD interventions, driven by a high incidence of ATP therapy in the TV-ICD group. The S- and TV-ICD patients experienced similar 5-year rate of device-related complications, albeit the risk of major lead-related complications was lower in S-ICD patients (HR: 0.17; 95%CI: 0.038-0.79; P = 0.023). The TV- and S-ICD patients displayed similar risk of disease-related complications (HR: 0.64; 95%CI: 0.27-1.52; P = 0.309) and mortality (HR: 0.74; 95%CI: 0.29-1.87; P = 0.521).Conclusion Hypertrophic cardiomyopathy patients implanted with a S-ICD had lower 5-year risk of appropriate and inappropriate ICD therapies as well as of major lead-related complications as compared to those implanted with a TV-ICD. Long-term comparative follow-up studies will clarify whether the lower incidence of major lead-related complications will translate into a morbidity or survival benefit. Graphical Abstract
引用
收藏
页数:9
相关论文
共 50 条
  • [31] CLINICAL COURSE OF MIDDLE-AGED ASYMPTOMATIC PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
    HECHT, GM
    PANZA, JA
    MARON, BJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (09): : 935 - 940
  • [32] Tissue Doppler imaging to predict clinical course of patients with hypertrophic cardiomyopathy
    Bayrak, Fatih
    Kahveci, Gokhan
    Mutlu, Bulent
    Sonmez, Kenan
    Degertekin, Muzaffer
    EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY, 2008, 9 (02): : 278 - 283
  • [33] Clinical course and genetic data in patients with familial and sporadic hypertrophic cardiomyopathy
    Oreshina, T
    Olbinskaya, L
    Parfenova, E
    Kaplunova, V
    INTERNATIONAL JOURNAL OF OBESITY, 2005, 29 : S11 - S11
  • [34] Usefulness of surface electrocardiogram in predicting the clinical course of patients with hypertrophic cardiomyopathy
    Bayrak, Fatih
    Kahveci, Goekhan
    Mutlu, Buelent
    Degertekin, Muzaffer
    Demirtas, Ertan
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2007, 7 : 178 - 181
  • [35] Hypertrophic cardiomyopathy in Greece - Clinical course and outcome
    Kyriakidis, M
    Triposkiadis, F
    Anastasakis, A
    Theopistou, A
    Tocta, R
    Barbetseas, J
    Gialafos, J
    CHEST, 1998, 114 (04) : 1091 - 1096
  • [36] Clinical Course and Management of Hypertrophic Cardiomyopathy REPLIES
    Maron, Barry J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (20): : 1977 - 1977
  • [37] High incidence of adequate implantable cardioverter-defibrillator interventions in patients with hypertrophic cardiomyopathy implanted for primary prevention
    Buschler, H
    Vogt, J
    Heintze, J
    Lamp, B
    Horstkotte, D
    Faber, L
    EUROPEAN HEART JOURNAL, 2004, 25 : 169 - 169
  • [38] Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy
    Maurizi, Niccolo'
    Olivotto, Iacopo
    Nordkamp, Louise R. A. Olde
    Baldini, Katia
    Fumagalli, Carlo
    Brouwer, Tom F.
    Knops, Reinoud E.
    Cecchi, Franco
    HEART RHYTHM, 2016, 13 (02) : 457 - 463
  • [39] Does Sport Participation Worsen the Clinical Course of Hypertrophic Cardiomyopathy? Clinical Outcome of Hypertrophic Cardiomyopathy in Athletes
    Pelliccia, Antonio
    Lemme, Erika
    Maestrini, Viviana
    Di Paolo, Fernando M.
    Pisicchio, Cataldo
    Di Gioia, Giuseppe
    Caselli, Stefano
    CIRCULATION, 2018, 137 (05) : 531 - 533
  • [40] Advantages of a Subcutaneous Implantable Cardioverter-Defibrillator in LAMP2 Hypertrophic Cardiomyopathy
    Zaki, Aly
    Zaidi, Amir
    Newman, William G.
    Garratt, Clifford J.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2013, 24 (09) : 1051 - 1053